Psychopharmacology
October 26, 2026
Jordi Jornet-Plaza, Carles Colom-Rocha, M Julia García-Fuster
Rationale Ketamine has emerged as a rapid-acting antidepressant drug for treatment-resistant depression in adults and is currently evaluated for adolescent depression. However, the long-term effects of ketamine exposure during this period of brain development remain unclear, particularly regarding addiction liability. Objectives To investigate whether repeated ketamine exposure during...
Psychopharmacology
October 26, 2026
Aline Frick, Grace Blest‐hopley, Manesh Girn et al.
Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, females remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex differences across multiple...
Journal of Affective Disorders
October 21, 2026
Yamina Ehrt-Schäfer, Georgios Schoretsanitis, Erich Seifritz et al.
Intranasal (es)ketamine has shown efficacy in therapy of treatment-resistant depression (TRD). However, its effects on suicidality have not been fully elucidated. We conducted a retrospective longitudinal cohort study of 80 patients affected by TRD, treated with intranasal (es)ketamine. Suicidality was assessed using item 10 of the clinician-rated Montgomery-Åsberg Depression Rating Scale...
Journal of Affective Disorders
September 23, 2026
Erin Curran, Kristina T. Kumpf, Mina Ansari et al.
Ketamine/esketamine produce rapid antidepressant effects, with growing interest in how acute subjective experiences and the surrounding set and setting shape clinical outcomes. Little is known about how audiovisual adjustments during ketamine/esketamine treatment influence comfort, tolerability, or patient experience, despite their common use in clinical practice. Virtual reality (VR) is one...
Journal of Neural Transmission
September 19, 2026
Guilherme Lodetti, Henrique Redivo, Amanda Gomes Teixeira et al.
Pharmacotherapy for depression is commonly prescribed, yet fewer than half of patients achieve remission with a single treatment. Many also experience intolerable side effects, highlighting the need for new treatment approaches. Classic psychedelics interact with the serotonin (5-HT) receptor class and are therefore strongly involved in the treatment of psychiatric illnesses such as depression,...
Frontiers in Psychology
September 17, 2026
Diana Brito Pearmain, Mark Kennedy, Karoly Schlosser
BackgroundPostgraduate students are six times more susceptible to mental health challenges than the general adult population, making it imperative to identify effective initiatives to support them. This is particularly relevant for master’s and doctorate students undertaking distance-learning programmes as this is a dimension of the student experience that remains unexplored. Meditation...
Psychiatry Research
September 14, 2026
Kelei Xiao, Yealin Woo, Christine E. Dri et al.
Cognitive impairment is a core feature of major depressive disorder (MDD) and bipolar disorder (BD). Most conventional antidepressants do not have direct and clinically relevant procognitive effects. Ketamine and esketamine are effective in treating treatment-resistant depression (TRD). Herein, this systematic review aims to evaluate the effects of both pharmacotherapeutics on cognitive...
Orvosi hetilap
September 13, 2026
Szabolcs Kéri
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...
PLoS One
September 9, 2026
J Richard T Korecki, Diana Winston, Elizabeth Ko et al.
Introduction: Nearly 80% of healthcare providers experience adverse psychological symptoms (e.g., depression, burnout, sleep disturbance) stemming from workplace stressors. Elevated levels of stress have been associated with unfavorable occupational, patient, and provider-related outcomes, imposing a heavy burden on a strained system. Given the impact of stress on both employee and patient...
Neuropsychological rehabilitation
September 7, 2026
Purani Bogahawatta, Ashan Wijekoon, Thameesha Harini et al.
Scientific interest in mindfulness meditation as complementary therapy for Parkinson's disease (PD) has grown significantly. This systematic review examined mindfulness meditation effects on PD motor, cognitive, falls-related (fear of falling (FoF), freezing of gait (FoG), falls prevention), psychological (anxiety and depression), physical (balance, mobility, gait velocity), and quality of life...